Literature DB >> 10762024

Multiagent chemopreventive agent combinations.

D E Brenner1.   

Abstract

Cancer chemoprevention is a new discipline whose foundation rests upon epidemiologic evidence suggesting that dietary components such as beta-carotene, vitamin E, calcium and selenium may be inhibitors of carcinogenesis. Over the last decade, as molecular and biochemical mechanisms of the carcinogenesis process have been elucidated, the rationale of combining chemopreventive agents to target multiple pathways has strengthened. The process of identifying potential synergistic combinations of chemoprevention agents should be based upon a systematic process of preclinical development in vitro followed by testing in animal models of carcinogenesis. Surrogates of anticarcinogenesis effects might include biochemical, molecular and pathologic assessment of tissue from animal carcinogenesis models. If evidence of chemopreventive effect is found in animal models, systematic studies in humans are indicated. These studies should include a careful Phase I trial to describe optimal chemoprevention doses for all agents being tested in combination followed by Phase II trials to assess efficacy upon carcinogenesis biological and pathological surrogates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762024     DOI: 10.1002/(sici)1097-4644(2000)77:34+<121::aid-jcb19>3.0.co;2-r

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  4 in total

1.  Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells.

Authors:  Vandanajay Bhatia; Miriam Falzon
Journal:  Cancer Lett       Date:  2015-04-03       Impact factor: 8.679

2.  Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.

Authors:  Dong M Shin; Sreenivas Nannapaneni; Mihir R Patel; Qiuying Shi; Yuan Liu; Zhengjia Chen; Amy Y Chen; Mark W El-Deiry; Jonathan J Beitler; Conor E Steuer; Steven M Roser; Adam M Klein; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Zhuo G Chen; Nabil F Saba
Journal:  Clin Cancer Res       Date:  2020-09-17       Impact factor: 12.531

3.  Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.

Authors:  Pamela Zengel; Diana Ramp; Brigitte Mack; Stefan Zahler; Alexander Berghaus; Bernd Muehlenweg; Olivier Gires; Suna Schmitz
Journal:  BMC Cancer       Date:  2010-03-11       Impact factor: 4.430

4.  Reducing tumor growth and angiogenesis using a triple therapy measured with Contrast-enhanced ultrasound (CEUS).

Authors:  Philipp Marius Paprottka; Svenja Roßpunt; Michael Ingrisch; Clemens C Cyran; Konstantin Nikolaou; Maximilian F Reiser; Brigitte Mack; Olivier Gires; Dirk A Clevert; Pamela Zengel
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.